Latest & greatest articles for gestational diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gestational diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on gestational diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for gestational diabetes

1. Association of Long-term Child Growth and Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes

Association of Long-term Child Growth and Developmental Outcomes With Metformin vs Insulin Treatment for Gestational Diabetes Metformin is an emerging option for treating gestational diabetes (GDM). However, because metformin crosses the placenta, patients and clinicians are concerned with its long-term effect on child health.To estimate the association of treating GDM with metformin vs insulin with child growth and development.Population-based cohort study of New Zealand women treated (...) with metformin or insulin for GDM from 2005 to 2012 and their children. This study linked national health care data to create a cohort of mothers and their children, including data from maternity care, pharmaceutical dispensing, hospitalizations, demographic records, and the B4 School Check (B4SC) preschool health assessment. Women treated pharmacologically with metformin or insulin during pregnancy were included. We excluded pregnancies with evidence of diabetes and deliveries prior to 2013. Liveborn

2019 EvidenceUpdates

2. Probiotics for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Women: Findings From the SPRING Double-blind Randomized Controlled Trial

Probiotics for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Women: Findings From the SPRING Double-blind Randomized Controlled Trial Given the role of gut microbiota in regulating metabolism, probiotics administered during pregnancy might prevent gestational diabetes mellitus (GDM). This question has not previously been studied in high-risk overweight and obese pregnant women. We aimed to determine whether probiotics (Lactobacillus rhamnosus and Bifidobacterium (...) % in the placebo arm (81 of 176) (P = 0.01). Rates of small for gestational age (<10th percentile) were 2.4% in the probiotics arm (5 of 205) and 6.5% in the placebo arm (13 of 199) (P = 0.042). There were no differences in other secondary outcomes.The probiotics used in this study did not prevent GDM in overweight and obese pregnant women.© 2019 by the American Diabetes Association.

2019 EvidenceUpdates

3. Prevalence of diabetes mellitus after gestational diabetes mellitus: a meta-analysis

Prevalence of diabetes mellitus after gestational diabetes mellitus: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

4. Autism spectrum disorder and attention deficit hyperactivity disorder in children affected by gestational diabetes: a systematic review and meta-analysis

Autism spectrum disorder and attention deficit hyperactivity disorder in children affected by gestational diabetes: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

5. Early gestational diabetes, neonatal outcomes and barriers: meta-analysis and qualitative synthesis.

Early gestational diabetes, neonatal outcomes and barriers: meta-analysis and qualitative synthesis. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

6. Serum levels of free fatty acids in gestational diabetes and their intrinsic determinants: systematic review and meta-analysis

Serum levels of free fatty acids in gestational diabetes and their intrinsic determinants: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

7. Risk of gestational diabetes mellitus (GDM) after assisted reproductive technologies (ART) compared with spontaneous conception in singleton pregnancies: a systematic review and meta-analysis

Risk of gestational diabetes mellitus (GDM) after assisted reproductive technologies (ART) compared with spontaneous conception in singleton pregnancies: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

8. The association between a history of hypertensive disorders of pregnancy (HDP) (preeclampsia or gestational hypertension) and the elevated risk of postpregnancy type 2 diabetes

The association between a history of hypertensive disorders of pregnancy (HDP) (preeclampsia or gestational hypertension) and the elevated risk of postpregnancy type 2 diabetes Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

9. Comparative efficacy and safety of metformin, glyburide and insulin in treating gestational diabetes mellitus: a meta-analysis

Comparative efficacy and safety of metformin, glyburide and insulin in treating gestational diabetes mellitus: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

10. Association of maternal visceral adipose tissue during pregnancy and gestational diabetes mellitus or dysglycemia: systematic review and meta-analysis

Association of maternal visceral adipose tissue during pregnancy and gestational diabetes mellitus or dysglycemia: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

11. Antioxidant nutrient intake, total antioxidant capacity and oxidative stress marker in women with gestational diabetes: systematic review and meta-analysis

Antioxidant nutrient intake, total antioxidant capacity and oxidative stress marker in women with gestational diabetes: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

12. Risk factors for foetal macrosomia in gestational diabetes mellitus: a systematic review

Risk factors for foetal macrosomia in gestational diabetes mellitus: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

13. Fetal, neonatal, and childhood outcomes of pregnancies affected by gestational diabetes mellitus treated with glyburide (glibenclamide)

Fetal, neonatal, and childhood outcomes of pregnancies affected by gestational diabetes mellitus treated with glyburide (glibenclamide) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

14. Diabetes prevention programs for women after gestational diabetes: an overview of reviews

Diabetes prevention programs for women after gestational diabetes: an overview of reviews Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

15. The experiences of the pregnant with gestational diabetes from confirmed to end of the delivery: a systematic review of qualitative evidence

The experiences of the pregnant with gestational diabetes from confirmed to end of the delivery: a systematic review of qualitative evidence Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

16. Improving the effectiveness of lifestyle interventions for gestational diabetes prevention: a meta-analysis and meta-regression

Improving the effectiveness of lifestyle interventions for gestational diabetes prevention: a meta-analysis and meta-regression Diet and exercise during pregnancy have been used to prevent gestational diabetes mellitus (GDM) with some success.To examine the effectiveness of lifestyle intervention on GDM prevention and to identify key effectiveness moderators to improve the prevention strategy.Pubmed, Scopus, Cochrane, and cross-references were searched.Randomised controlled trials (RCTs (...) the preventive effect: targeting the high-risk population; an early initiation of the intervention; the correct intensity and frequency of exercise; and gestational weight gain management. Although 24 RCTs targeted women who were overweight or obese, body mass index (BMI) failed to predict the effectiveness of an intervention. Instead, interventions are most effective in high-incidence populations rather than simply in women who are overweight or obese. Furthermore, exercise of moderate intensity for 50-60

2018 EvidenceUpdates

17. Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs

Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs Gestational diabetes mellitus is defined as carbohydrate intolerance that begins or is first recognized during pregnancy. Insulin sensitizing substances such as myo-inositol have been considered for the prevention of gestational diabetes mellitus and related complications.Because previous studies failed to show a clear reduction (...) of gestational diabetes mellitus complications, the aim of this study was to evaluate clinical and metabolic outcomes in women who are at risk for gestational diabetes mellitus supplemented with myo-inositol since the first trimester.A secondary analysis of databases from 3 randomized, controlled trials (595 women enrolled) in which women who were at risk for gestational diabetes mellitus (a parent with type 2 diabetes mellitus, obese, or overweight) were supplemented with myo-inositol (4 g/d) throughout

2018 EvidenceUpdates

18. A Pre-Pregnancy Biomarker Risk Score Improves Prediction of Future Gestational Diabetes (PubMed)

A Pre-Pregnancy Biomarker Risk Score Improves Prediction of Future Gestational Diabetes Previous studies have not examined the ability of multiple preconception biomarkers, considered together, to improve prediction of gestational diabetes mellitus (GDM).To develop a preconception biomarker risk score and assess its association with subsequent GDM.A nested case-control study among a cohort of women with serum collected as part of a health examination (1984 to 1996) and subsequent pregnancy (...) of diabetes, previous GDM; area under the curve = 0.73 vs 0.67, P = 0.002).The improved, predictive ability of the biomarker risk score beyond established risk factors suggests clinical use of the biomarker risk score in identifying women at risk for GDM before conception for targeted prevention strategies.

Full Text available with Trip Pro

2018 Journal of the Endocrine Society

19. Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity. (PubMed)

Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity. The sequelae of gestational diabetes (GD) by contemporary criteria that diagnose approximately twice as many women as previously used criteria are unclear.To examine associations of GD with maternal glucose metabolism and childhood adiposity 10 to 14 years' postpartum.The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study established associations of glucose levels during pregnancy (...) with perinatal outcomes and the follow-up study evaluated the long-term outcomes (4697 mothers and 4832 children; study visits occurred between February 13, 2013, and December 13, 2016).Gestational diabetes was defined post hoc using criteria from the International Association of Diabetes and Pregnancy Study Groups consisting of 1 or more of the following 75-g oral glucose tolerance test results (fasting plasma glucose ≥92 mg/dL; 1-hour plasma glucose level ≥180 mg/dL; 2-hour plasma glucose level ≥153 mg/dL

Full Text available with Trip Pro

2018 JAMA

20. Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews. (PubMed)

Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews. Successful treatments for gestational diabetes mellitus (GDM) have the potential to improve health outcomes for women with GDM and their babies.To provide a comprehensive synthesis of evidence from Cochrane systematic reviews of the benefits and harms associated with interventions for treating GDM on women and their babies.We searched the Cochrane Database of Systematic Reviews (5 January 2018 (...) (hypertensive disorders of pregnancy, pregnancy-induced hypertension, death or serious morbidity composite, insulin versus oral therapy (development of type 2 diabetes); intensive management versus routine care (IOL, large-for-gestational age); post- versus pre-prandial glucose monitoring (large-for-gestational age). The evidence ranged from moderate-, low- and very low-quality.Currently there is insufficient high-quality evidence about the effects on health outcomes of relevance for women with GDM

Full Text available with Trip Pro

2018 Cochrane